KAMADA » CLINICAL PIPELINE » RECOMBINANT AAT

RECOMBINANT AAT

In preparation for future increased demand for AAT resulting from greater awareness of AAT deficiency, as well as potential additional indications for Alpha 1 Antitrypsin, which are currently in clinical development, we have initiated development activities in the recombinant human Alpha-1 Antitrypsin ("rhAAT") field.

To ensure the success of this project, we have previously developed analytical methods (physicochemical, biochemical, in-vitro, and in-vivo) that will help identify and characterize
functional rhAAT. In addition, we have established a significant understanding of a favorable expression system and growth conditions required to successfully develop an effective rhAAT
and we are exploring potential collaborations with third parties in the development of rhAAT.